Trials / Unknown
UnknownNCT05981066
A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma
An Open, Single-center, Multiple-dose, Dose-increasing and Dose-expanding Clinical Study to Observe and Evaluate the Safety, Tolerance, Immunokinetics and Preliminary Effectiveness of ABOR2014 Injection (IPM511) in the Treatment of Advanced Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, investigator-initiated trial designed to evaluate the safety, tolerability and preliminary efficacy of ABOR2014(IPM511) injection in relapsed/ refactory HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoantigen vaccine, I.M injection | Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered. |
Timeline
- Start date
- 2023-07-10
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2023-08-08
- Last updated
- 2023-08-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05981066. Inclusion in this directory is not an endorsement.